login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
HCW BIOLOGICS INC (HCWB) Stock News
USA
-
Nasdaq
- NASDAQ:HCWB -
US40423R2040
-
Common Stock
1.92
USD
-0.25 (-11.52%)
Last: 11/25/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
HCWB Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: HCW Biologics Inc.
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
8 days ago - By: HCW Biologics Inc.
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
9 days ago - By: Benzinga
- Mentions:
AIM
NUVL
GLMD
VTGN
...
12 Health Care Stocks Moving In Monday's After-Market Session
9 days ago - By: Benzinga
- Mentions:
JAZZ
AEMD
BYSI
ZYME
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 days ago - By: HCW Biologics Inc.
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
3 months ago - By: The Motley Fool
Hcw Biologics Revenue Plunges 98 Percent
19 days ago - By: HCW Biologics Inc.
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
a month ago - By: HCW Biologics Inc.
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment
a month ago - By: HCW Biologics Inc.
HCW Biologics to Participate in the 2025 Maxim Growth Summit
a month ago - By: HCW Biologics Inc.
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
2 months ago - By: HCW Biologics Inc.
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
2 months ago - By: HCW Biologics Inc.
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
2 months ago - By: HCW Biologics Inc.
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
3 months ago - By: HCW Biologics Inc.
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
3 months ago - By: HCW Biologics Inc.
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
3 months ago - By: HCW Biologics Inc.
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
Please enable JavaScript to continue using this application.